使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings. Welcome to the Bausch Health fourth quarter and full-year 2023 earnings call. (Operator Instructions)
各位好。歡迎參加 Bausch Health 2023 年第四季及全年財報電話會議。(接線員指示)
Please note this conference is being recorded. I would now like to turn the conference over to your host, [Maria Likuris]. You may begin.
請注意,本次會議將被錄音。現在我想把會議交給您的主持人,[Maria Likuris]。您可以開始了。
Unidentified Participant
Unidentified Participant
Good morning, and welcome to Bausch Health's fourth-quarter 2023 earnings conference call. Participating in today's call are Thomas Appio, Chief Executive Officer of Bausch Health; and John Barresi, Interim Chief Financial Officer.
早安,歡迎參加 Bausch Health 2023 年第四季財報電話會議。今天參與會議的有 Bausch Health 執行長 Thomas Appio,以及代理財務長 John Barresi。
Before we begin, I'd like to remind you that our presentation today contains forward-looking information. We ask you to take a moment to read the forward-looking statements disclaimer at the beginning of the slides that accompany this presentation as it contains important information.
在開始之前,我想提醒各位,我們今天的簡報包含前瞻性資訊。請您花一點時間閱讀本簡報投影片開頭的前瞻性聲明免責聲明,其中包含重要資訊。
Our actual results may vary materially from those expressed or implied in our forward-looking statements, and you should not place undue reliance on any forward-looking statements. Please refer to our SEC filings and filings with the Canadian securities administrators for a list of some of the risk factors that could cause our actual results to differ materially from our expectations.
我們的實際結果可能與前瞻性聲明中明示或暗示的內容有重大差異,您不應過度依賴任何前瞻性聲明。請參閱我們向 SEC 提交的文件以及向加拿大證券主管機關提交的文件,其中列示部分可能導致實際結果與預期有重大差異的風險因素。
We use non-GAAP financial measures to help investors understand our on business performance. Non-GAAP financial measures may not comparable to similarly titled measures used by other companies and should not be considered along with, but not as an alternative to, measures calculated in accordance with GAAP. You will find reconciliations to our non-GAAP measures in the appendix of the slides that accompany this presentation, which are available on Bausch Health's Investor Relations website.
我們使用非 GAAP 財務衡量指標,以協助投資人了解我們的業務表現。非 GAAP 財務衡量指標可能無法與其他公司使用的同名指標相比,且應與依 GAAP 計算的指標一併考量,但不應作為其替代。您可在隨附本簡報之投影片附錄中找到我們非 GAAP 指標的調節表;投影片可於 Bausch Health 投資人關係網站取得。
Finally, the financial guidance in this presentation is effective as of today only. We do not undertake any obligation to update guidance. Our discussion today will focus on Bausch Health, excluding Bausch + Lomb. However, we will briefly comment on Bausch + Lomb's results announced yesterday. We will refer to year-over-year comparisons with the same period last year unless otherwise noted.
最後,本簡報中的財務指引僅於今日有效。我們不承擔更新指引的任何義務。我們今天的討論將聚焦於 Bausch Health,不包含 Bausch + Lomb。不過,我們將簡要評論 Bausch + Lomb 昨日公布的業績。除非另有說明,我們將以與去年同期的年對年比較為準。
For the benefit of those who may be listening to the replay or archived webcast, this call was held on and recorded on February 22, 2024.
為了方便收聽重播或存檔網路直播的聽眾,本次電話會議於 2024 年 2 月 22 日舉行並錄製。
With that, it is my pleasure to turn the call over to our CEO, Thomas Appio. Tom?
接下來,我很榮幸把電話會議交給我們的執行長 Thomas Appio。Tom?
Thomas Appio - CEO
Thomas Appio - CEO
Thank you, and welcome to those of you joining the call this morning. I want to start today's call by highlighting the strategic priorities we set out to achieve this past year, growth, performance, focus, and unlocking value. These priorities help support our ambition of being a globally integrated healthcare company trusted and valued by patients, healthcare providers, employees, and investors, as we relentlessly drive to deliver better health outcomes.
謝謝,也歡迎各位今天早上加入本次電話會議。我想先強調我們在過去一年設定並致力達成的策略優先事項:成長、績效、聚焦,以及釋放價值。這些優先事項有助於支持我們的願景:成為一家全球整合的醫療保健公司,獲得病患、醫療服務提供者、員工與投資人信任與重視,同時我們持續不懈地推動更佳的健康成果。
We made significant progress on these priorities in 2023, reinforcing our strong global foundation, which consists of a large portfolio of products across a diverse set of therapeutic areas and geographies.
我們在 2023 年於這些優先事項上取得重大進展,進一步鞏固我們強大的全球基礎;該基礎由涵蓋多元治療領域與地理市場的大型產品組合所構成。
Our significant presence in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, and international pharmaceuticals across the branded, generic, and branded-generic markets give us a solid platform for growth, as we are excited about the opportunities in each of these areas.
我們在腸胃科、肝膽科、神經科、皮膚科、醫療美容器材,以及國際藥品領域(涵蓋品牌藥、學名藥與品牌學名藥市場)具備顯著布局,為成長提供穩固平台;我們對各領域的機會都感到振奮。
From a financial perspective, I am pleased to report we achieved or exceeded our February 2023 guidance. For Bausch Health, excluding B&L, full-year revenue was $4.61 billion, and organic revenue growth was 6%, both slightly above our February 2023 guidance range and in line with our guidance update in November.
從財務角度來看,我很高興報告我們達成或超越 2023 年 2 月所提供的指引。就 Bausch Health(不含 B&L)而言,全年營收為 46.1 億美元,有機營收成長為 6%;兩者皆略高於 2023 年 2 月指引區間,並與 11 月更新的指引一致。
For Bausch Health, excluding B&L, full-year adjusted EBITDA was $2.36 billion, in line with our guidance, while funding incremental spend on R&D to support our RED-C and amiselimod programs.
就 Bausch Health(不含 B&L)而言,全年調整後 EBITDA 為 23.6 億美元,符合我們的指引,同時也支應了為支持 RED-C 與 amiselimod 計畫而增加的研發投入。
Importantly, we ended the year on a strong note, as the fourth quarter represented our third consecutive quarter of year-over-year growth in adjusted EBITDA, and we delivered adjusted operating cash flow of $708 million above our guidance.
重要的是,我們以強勁表現結束年度:第四季為調整後 EBITDA 連續第三季年對年成長,且我們交付的調整後營運現金流為 7.08 億美元,高於我們的指引。
For the fourth quarter, revenues for Bausch Health, excluding B&L, were $1.24 billion, up $38 million or 3% on a reported basis and 2% on an organic basis. Adjusted EBITDA was $663 million, an increase of approximately 1% compared to the prior year.
第四季方面,Bausch Health(不含 B&L)營收為 12.4 億美元,按申報基礎增加 3%(增加 3,800 萬美元),按有機基礎增加 2%。調整後 EBITDA 為 6.63 億美元,較去年同期約增加 1%。
We made significant progress across our key R&D initiatives during the quarter. First, we received a positive top line data from our large global Phase II trial for amiselimod. Second, we completed enrollment for one of our two global Phase III trials for RED-C, with the second trial expected to complete enrollment in the first half of this year. And third, in January, we received approval by the National Medical Products Administration, or NMPA, for Thermage FLX and the TR-4 return pad in China.
本季我們在關鍵研發計畫上取得重大進展。第一,我們的 amiselimod 大型全球第二期試驗取得正面的主要結果數據。第二,我們完成 RED-C 兩項全球第三期試驗之一的受試者收案,預期第二項試驗將於今年上半年完成收案。第三,在 1 月,我們取得中國國家藥品監督管理局(NMPA)對 Thermage FLX 與 TR-4 回路貼片(return pad)在中國的核准。
I will touch on these in more detail shortly. I am pleased with the continued momentum in our pipeline.
我稍後會更詳細說明這些事項。我對我們研發管線持續的動能感到滿意。
Strengthening our balance sheet also remains a priority, as we are focusing on managing our liquidity position. During 2023, we reduced debt net of cash for Bausch Health, excluding B&L by $670 million. And in January 2024, we retired an additional $250 million in principal value of debt through an open market repurchase program.
強化資產負債表仍是優先事項之一,我們正聚焦於管理流動性狀況。在 2023 年,我們將 Bausch Health(不含 B&L)的淨負債(扣除現金後)降低 6.7 億美元。而在 2024 年 1 月,我們透過公開市場回購計畫,額外償還了 2.5 億美元的債務本金。
We continued to defend our intellectual property rights for XIFAXAN. As discussed on our third quarter 2023 earnings call on October 6, 2023, the D.C. District Court held a hearing in Norwich's lawsuit against the FDA, where Norwich was seeking immediate approval of their ANDA.
我們持續捍衛 XIFAXAN 的智慧財產權。如同我們在 2023 年 10 月 6 日第三季財報電話會議所討論的,華盛頓特區地方法院就 Norwich 對 FDA 提起的訴訟舉行聽證會;Norwich 當時尋求其 ANDA 立即獲准。
On November 1, the court denied Norwich's motion and granted summary judgment in favor of the FDA and Salix. In December, Norwich appealed the District Court's decision to the US Court of Appeals for the D.C. Circuit. The D.C. Circuit has stayed the appeal until the Federal Circuit renders the decision in our XIFAXAN litigation.
11 月 1 日,法院駁回 Norwich 的動議,並作出有利於 FDA 與 Salix 的簡易判決。12 月,Norwich 就地方法院裁決向美國哥倫比亞特區巡迴上訴法院提出上訴。在聯邦巡迴上訴法院就我們的 XIFAXAN 訴訟作出裁決之前,特區巡迴上訴法院已暫緩該上訴程序。
The consolidated appeals from the Delaware District Court are pending at the US Court of Appeals for the Federal Circuit. On January 8, the Federal Circuit heard oral arguments. We expect a decision to follow late in the first quarter or early in the second quarter. We are committed to vigorously defending our intellectual property and providing health care providers and patients with safe and effective treatments.
源自特拉華州地方法院的合併上訴案目前正在美國聯邦巡迴上訴法院審理中。1 月 8 日,聯邦巡迴上訴法院已聽取口頭辯論。我們預期裁決將於第一季末或第二季初出爐。我們致力於積極捍衛智慧財產權,並為醫療服務提供者與病患提供安全且有效的治療。
You will recall that in January of 2023, we reached a tentative settlement with the IRS to resolve the Granite Trust matter. We continue to expect this settlement to be finalized in the coming months as we have previously said. The anticipated outcome of the settlement does not have a material impact on the company's results or cash flows.
各位或許記得,我們在 2023 年 1 月與 IRS 達成暫定和解,以解決 Granite Trust 事項。如同先前所述,我們仍預期該和解將在未來數月內完成定案。該和解的預期結果不會對公司業績或現金流造成重大影響。
Turning now to the potential full separation of Bausch + Lomb. We continue to believe the separation of Bausch + Lomb makes strategic sense, and we continue to evaluate strategies regarding the potential full separation with the objective of ensuring that this transaction results in two appropriately capitalized companies.
接著談到 Bausch + Lomb 可能的完全分拆。我們仍相信分拆 Bausch + Lomb 在策略上合理,並持續評估可能完全分拆的相關策略,目標是確保該交易完成後形成兩家資本結構適當的公司。
Any decision regarding if and when a separation occurs or its structure will be based on and subject to an assessment of all relevant factors and circumstances, any potential separation will also be subject to shareholder and other applicable approvals.
任何關於是否以及何時進行分拆或其架構的決定,都將以對所有相關因素與情況的評估為基礎並受其約束;任何潛在分拆亦將須取得股東及其他適用之核准。
And in the meantime, we are focused on managing our balance sheet. We ended the quarter with $1.5 billion of liquidity. We repurchased a small amount of debt in the fourth quarter and in January 2024, repurchased approximately $250 million in principal value of our debt.
同時,我們也專注於管理我們的資產負債表。本季末我們的流動性為15億美元。我們在第四季以及2024年1月回購了少量債務,於2024年1月回購了約2.5億美元本金金額的債務。
Finally, we are introducing our 2024 guidance for Bausch Health, excluding B&L, which reflects our confidence that we can deliver top and bottom-line growth again in 2024. John will speak in more detail to this later in the call.
最後,我們提出Bausch Health(不含B&L)的2024年財測指引,反映我們有信心在2024年再次實現營收與獲利(上下線)成長。John稍後將在本次電話會議中更詳細說明。
Turning now to an overview of our segment performance for the quarter. In Salix, we continued to see strong demand in Q4 for our key products, including XIFAXAN. For XIFAXAN, we saw approximately 3% TRx growth in Q4 over the prior year, with a strengthening trend in the back half of the quarter. This was led by strong growth for IBS-D with a return to growth for HE driven by long-term care channel.
接下來概述本季各事業部門的表現。在Salix方面,我們在第四季持續看到核心產品(包括XIFAXAN)的強勁需求。就XIFAXAN而言,第四季TRx較去年同期約成長3%,且在本季後半段呈現走強趨勢。此成長主要由IBS-D的強勁成長帶動,而HE在長期照護通路的推動下也重回成長。
Putting this all together, we believe we are starting to see the benefits of our investments in AI-enabled sales force tools and DTC advertising to spread awareness of the underlying medical conditions and the options that are available to treat them.
綜合以上,我們相信我們開始看到對AI賦能的銷售團隊工具與DTC(直接面向消費者)廣告投資所帶來的效益,這些投資有助於提升對潛在醫療狀況的認知,以及可用治療選項的了解。
For 2024, we anticipate maintaining our current level of investment in these areas to drive further growth in this important franchise. Finally, Trulance and Relistor continued to deliver double-digit TRx growth in the quarter.
展望2024年,我們預期將維持在這些領域的目前投資水準,以推動這個重要產品組合的進一步成長。最後,Trulance與Relistor在本季持續繳出TRx雙位數成長。
Turning to international. We saw strong year-over-year revenue growth on both a reported and organic basis in all regions during the fourth quarter, continued growth in our promoted brand portfolios in key markets, including Poland, Mexico, and Canada, more than offset the impact of the Emerade recall earlier in 2023 and increased generic competition for certain products, particularly in Canada. Our focus in 2024 will be continuing to invest in our promoted product portfolio while looking for business development opportunities to drive long-term growth.
接著談國際市場。第四季各區域在報告基礎與有機基礎下均呈現強勁的年增營收成長;我們在關鍵市場(包括波蘭、墨西哥與加拿大)的主推品牌組合持續成長,足以抵銷2023年稍早Emerade召回的影響,以及部分產品(尤其在加拿大)面臨更激烈的學名藥競爭。我們在2024年的重點將是持續投資於主推產品組合,同時尋找業務開發機會,以推動長期成長。
In Solta Medical, revenues increased by 4% on a reported and 5% on an organic basis, reflecting solid growth in China as well as growth in the broader Asia Pacific region. Revenues in the US declined slightly in the quarter. We remain highly focused on maintaining our momentum in Asia, including driving Thermage FLX performance in China. And in 2024, we'll also be focused on growing our US and EMEA markets, where we believe there is meaningful opportunity to expand our presence.
在Solta Medical方面,營收在報告基礎下成長4%、在有機基礎下成長5%,反映中國的穩健成長以及更廣泛亞太地區的成長。美國市場營收在本季略有下滑。我們仍高度專注於維持在亞洲的動能,包括推動Thermage FLX在中國的表現。而在2024年,我們也將著重成長美國與EMEA市場,我們相信在這些市場擴大布局具有顯著機會。
To support these efforts, we have added talented key leadership to the Solta business to advance our leading portfolio of products and have invested in the expansion of the U.S. field force. We are also focusing our R&D organization on our pipeline of new market authorizations and next-generation products, as we continue to build upon this world-class durable aesthetics business.
為支持這些工作,我們已為Solta業務增添優秀的關鍵領導人才,以推進我們領先的產品組合,並投資擴編美國前線銷售團隊。我們也將研發組織聚焦於新市場核准與次世代產品的研發管線,持續打造這項世界級、具耐久性的醫美業務。
In diversified, we saw another quarter of healthy performance, particularly in neurology, as we continue to capitalize on opportunities in the market created by competitors' supply constraints. We remained focused on managing this mature portfolio of products for profitability and cash generation in a challenging, competitive, and pricing environment and continued to look for opportunities to make targeted investments where appropriate.
在多元化(diversified)事業方面,我們再度交出健康表現的一季,尤其在神經科領域,因我們持續把握競爭對手供應受限所創造的市場機會。在充滿挑戰、競爭激烈且價格壓力的環境下,我們仍專注於以獲利能力與現金創造為目標來管理這個成熟的產品組合,並持續尋找在適當情況下進行精準投資的機會。
Dentistry revenues were in line with a strong Q4 in the prior year. And in the coming year, we are looking to accelerate growth with a focus on the sales force and new marketing tools. In Dermatology, CABTREO is now launched and available for patients in the US at the end of January 2024, and we are excited to be able to provide this new once-a-day triple combination topical acne treatment for patients. We continue to expect that CABTREO will be launched in Canada in the second half of 2024.
牙科營收與去年同期強勁的第四季表現相當。在接下來一年,我們將聚焦銷售團隊與新的行銷工具,以加速成長。在皮膚科方面,CABTREO已於2024年1月底在美國上市並可供病患使用,我們很高興能為病患提供這款每日一次的三合一外用痤瘡治療新選擇。我們仍預期CABTREO將於2024年下半年在加拿大上市。
Turning to the latest developments in our R&D pipeline, starting with our GI pipeline. In December, we announced positive top-line results from our Phase II study evaluating amiselimod, an S1P antagonist in the treatment of ulcerative colitis or UC. We are very pleased that the study met the primary and key secondary endpoints, including clinical remission and endoscopic improvement during the double-blind period of the study with no unexpected adverse events.
接著更新我們研發管線的最新進展,先從腸胃(GI)管線開始。12月,我們公布第二期研究的正向主要結果,該研究評估amiselimod(一種S1P拮抗劑)用於治療潰瘍性結腸炎(UC)。我們非常高興該研究達成主要與關鍵次要終點,包括在雙盲期達到臨床緩解與內視鏡改善,且未出現非預期不良事件。
We are preparing for our next steps to progress this program, including presenting the detailed results at upcoming scientific conferences and planning to meet with the FDA for an end of Phase II meeting. We are planning to advance into Phase III in moderate to severe UC patients and could possibly target all UC patients based on our results.
我們正為推進此計畫的下一步做準備,包括在即將到來的科學會議上發表詳細結果,並規劃與FDA進行第二期結束(end of Phase II)會議。我們計畫在中重度UC病患中推進至第三期,並可能根據研究結果將目標擴及所有UC病患。
We anticipate a step-up in R&D spend to support these Phase III efforts as well as exploring opportunities to expand into other therapeutic areas, primarily Crohn's disease with a Phase II program. We expect to initiate our global Phase III program for UC in late 2024.
我們預期研發支出將增加,以支持這些第三期工作,同時也探索擴展至其他治療領域的機會,主要是以第二期計畫切入克隆氏症。我們預計於2024年末啟動UC的全球第三期計畫。
Our RED-C program for rifaximin for reduction of early decompensation in cirrhosis continues to advance. The global program is focused on delivering a novel formulation and assessing the efficacy of rifaximin SSD formulation versus placebo to delay the occurrence of HE related hospitalizations.
我們的RED-C計畫(以rifaximin用於降低肝硬化早期失代償)持續推進。此全球計畫聚焦於提供一種新劑型,並評估rifaximin SSD劑型相較安慰劑在延緩與HE相關住院發生方面的療效。
We completed enrollment for one of two large global Phase III trials as of the end of the year with enrollment for the second trial expected to be completed during the first half of 2024. Together, these studies are expected to include approximately 1,000 patients across the major markets of North America, Europe, and Asia Pacific.
截至年底,我們已完成兩項大型全球第三期試驗中的其中一項收案;第二項試驗預期將於2024年上半年完成收案。合計而言,這些研究預計將在北美、歐洲與亞太等主要市場納入約1,000名病患。
Turning now to our aesthetics pipeline. We are very pleased to have received approval for Thermage FLX and TR-4 return pad from the NMPA in China in January. We are excited about the opportunities in this market, and we see a runway for growth. We expect to start realizing the benefits of this starting in the second quarter of this year.
接著談我們的醫美研發管線。我們非常高興在1月於中國獲得NMPA對Thermage FLX與TR-4回路貼片(return pad)的核准。我們對該市場的機會感到振奮,並看見成長的長期空間。我們預期自今年第二季起開始實現其效益。
We plan an FDA submission for our Next Generation Fraxel, a fractionated laser device for skin resurfacing in the second quarter of 2024. We expect approval could be received in the second half of this year.
我們計畫於2024年第二季向FDA提交下一代Fraxel(用於皮膚換膚的分段式雷射裝置)的申請。我們預期可於今年下半年取得核准。
Finally, our program for Clear + Brilliant Touch, a fractionated laser device for skin rejuvenation continues to advance with regulatory submissions still on track for 2024 in Europe, Canada, and Asia Pacific markets.
最後,我們的Clear + Brilliant Touch計畫(用於皮膚年輕化的分段式雷射裝置)持續推進,法規申請仍按計畫於2024年在歐洲、加拿大與亞太市場進行。
As a leadership team, we remain committed to driving growth by leveraging our existing assets making targeted investments and executing with commercial excellence while continuing to progress our pipeline, all with a patient-centered mentality.
作為領導團隊,我們仍致力於透過善用既有資產、進行精準投資並以卓越的商業執行來推動成長,同時持續推進研發管線,並以病患為中心的理念貫穿其中。
With that, I will turn the call over to John Barresi, who will provide further details on our fourth-quarter performance and financial outlook for 2024. John?
接下來,我將把電話會議交給John Barresi,他將就我們第四季表現與2024年財務展望提供更多細節。John?
John Barresi - Interim CFO
John Barresi - Interim CFO
Thanks, Tom. Hello, everyone, and thanks for joining us.
謝謝你,Tom。各位好,感謝大家加入我們。
We closed the fourth quarter with consolidated revenues of Bausch Health at $2.41 billion, up 10% on a reported basis and 4% on an organic basis over the same quarter last year. On a consolidated basis, revenue increased 8% for the full year on a reported basis and 7% on an organic basis.
我們以Bausch Health合併營收24.1億美元結束第四季,較去年同期在報告基礎下成長10%,在有機基礎下成長4%。以合併基礎計算,全年營收在報告基礎下成長8%,在有機基礎下成長7%。
Fourth-quarter revenues for Bausch Health, excluding B&L, were $1.24 billion, up 3% on a reported basis and up 2% on an organic basis over the same quarter last year, with growth in our international, diversified, and Solta segments, while Salix was in line with last year.
Bausch Health(不含B&L)第四季營收為12.4億美元,較去年同期在報告基礎下成長3%,在有機基礎下成長2%;國際、多元化與Solta部門帶動成長,而Salix與去年持平。
Bausch Health, excluding B&L, ended the year with revenues of $4.61 billion, of $255 million or 6% on both a reported and organic basis compared to 2022.
Bausch Health(不含 B&L)年末營收為 46.1 億美元,較 2022 年在申報口徑與有機口徑均增加 2.55 億美元或 6%。
Let's dive into the revenue performance for each segment in more detail, starting on slide 13 with Salix. Fourth-quarter Salix revenues increased $2 million on both an organic and reported basis to $583 million, driven by TRx growth in our key products, including XIFAXAN, RELISTOR, and Trulance. Comparisons to the prior year's quarter were impacted by changes in the timing of wholesaler buying patterns.
讓我們更深入檢視各事業部門的營收表現,先從第 13 頁投影片的 Salix 開始。第四季 Salix 營收在有機與申報口徑均增加 200 萬美元至 5.83 億美元,主要受我們關鍵產品(包括 XIFAXAN、RELISTOR 與 Trulance)TRx 成長帶動。與去年同期相比的比較受到批發商採購時點變動的影響。
As you will recall, sales reported 13% growth in the third quarter of 2023 compared to the third quarter of 2022.
如各位所記得,2023 年第三季的銷售額較 2022 年第三季成長 13%。
As we noted then, we saw an increase in wholesale channel inventory in Q3 earlier than we had anticipated. And this quarter, we saw inventory in the wholesale channel decline compared to a build in Q4 of 2022.
正如我們當時所提到的,我們在第三季看到批發通路庫存增加的時間點比原先預期更早。而在本季,我們看到批發通路庫存下降,相較之下 2022 年第四季則是庫存增加。
For the full year, Salix reported revenues of $2.25 billion, an increase of approximately 8% over 2022 on a reported basis. We realized an approximately 3% increase in net price along with an approximately 5% increase in volume, with the volume increase split roughly equally between underlying demand and the impact of higher overall wholesale inventory levels year over year. While inventory in the channel declined relative to Q3, we did end the year higher than we ended 2022.
全年而言,Salix 申報營收為 22.5 億美元,較 2022 年申報口徑增加約 8%。我們實現約 3% 的淨價格提升,以及約 5% 的銷量成長;其中銷量成長約一半來自基礎需求,另一半來自整體批發庫存水位年增的影響。雖然通路庫存相較第三季有所下降,但年末庫存仍高於 2022 年年末水準。
XIFAXAN continued to represent approximately 80% of Salix segment revenues this year and saw strong growth in underlying demand. Retail prescriptions grew 3.1% in Q4 versus the prior quarter. We saw growth in TRx for IBS-D and importantly, we also saw solid growth of approximately 6% year over year in Q4 in TRx for the long-term care channel as well as strong growth in non-retail units attributable to out-patient clinics.
XIFAXAN 今年仍約占 Salix 事業部營收的 80%,且基礎需求強勁成長。第四季零售處方量較前一季成長 3.1%。我們看到 IBS-D 的 TRx 成長;更重要的是,我們也看到長期照護通路的 TRx 在第四季年增約 6%,以及由門診診所帶動的非零售單位數強勁成長。
For the quarter, XIFAXAN revenues were in line with the prior year as the TRx growth was offset by the timing of wholesaler buying patterns discussed earlier.
就本季而言,XIFAXAN 營收與去年同期持平,因 TRx 成長被前述批發商採購時點的影響所抵銷。
For the quarter, RELISTOR delivered 44% growth over the prior year due to both higher demand and improved net pricing, while Trulance revenues were flat, as TRx growth was offset by lower net pricing and shifts in wholesale inventory.
就本季而言,RELISTOR 受需求提升與淨價格改善雙重帶動,較去年同期成長 44%;而 Trulance 營收持平,因 TRx 成長被較低的淨價格與批發庫存變動所抵銷。
International revenues were $290 million during the quarter, an increase of 11% on a reported basis and 6% on an organic basis compared to the prior year period, with strong performances across the EMEA, Canada, and Latin America regions.
本季國際營收為 2.90 億美元,較去年同期申報口徑成長 11%、有機口徑成長 6%,EMEA、加拿大與拉丁美洲地區表現強勁。
For the full year, international revenues were $1.07 billion for 2023 compared to $988 million for 2022, an increase of $83 million or 8% on a reported basis and 6% on an organic basis. This year's international segment performance was driven mainly by an increase in net realized pricing, as growth in our portfolio of promoted products was offset by the impact of increased generic competition and the effects of the Emerade recall in the second quarter.
2023 年全年國際營收為 10.7 億美元,較 2022 年的 9.88 億美元增加 8,300 萬美元或 8%(申報口徑),有機口徑成長 6%。今年國際事業部的表現主要由淨實現價格上升所帶動,因我們推廣產品組合的成長被學名藥競爭加劇的影響,以及第二季 Emerade 召回事件的影響所抵銷。
Solta Medical revenues were $103 million for the fourth quarter, an increase of 4% on a reported basis and 5% on an organic basis over the prior year period. Growth in the quarter was led by China and to a lesser degree, the remainder of Asia Pacific, while sales in the US slightly declined compared to the prior year.
Solta Medical 第四季營收為 1.03 億美元,較去年同期申報口徑成長 4%、有機口徑成長 5%。本季成長主要由中國帶動,其次為亞太其他地區;而美國銷售較去年同期略為下滑。
Solta Medical ended the year with revenues of $347 million, an increase of 16% on a reported basis and 18% on an organic basis compared to 2022. Revenue growth was driven by strong demand in China, including the effect of comparison to 2022 in China, and to a lesser degree, the rest of the Asia Pacific region were affected by COVID-related lockdowns.
Solta Medical 年末營收為 3.47 億美元,較 2022 年申報口徑成長 16%、有機口徑成長 18%。營收成長由中國強勁需求帶動,其中包含與 2022 年在中國的比較基期效應;此外,亞太其他地區也在一定程度上受到與 COVID 相關封控的影響。
With approximately 80% of the revenue for this business coming from consumables, the recent Thermage FLX approval in China and possible untapped potential in the US and EMEA, we believe Solta Medical is positioned for continued near and long-term growth globally.
由於該業務約 80% 的營收來自耗材,加上 Thermage FLX 近期在中國獲批,以及美國與 EMEA 可能尚未充分開發的潛力,我們相信 Solta Medical 已具備在全球持續實現短期與長期成長的有利定位。
Diversified revenues were $259 million during the fourth quarter, an increase of 1% on a reported basis and 2% on an organic basis compared to the prior year period. Neurology delivered year-over-year growth, as we continue to capitalize on opportunities in the market created by supply constraints among competing products in the fourth quarter.
多元化業務第四季營收為 2.59 億美元,較去年同期申報口徑成長 1%、有機口徑成長 2%。神經科業務實現年增成長,因我們持續把握第四季競品供應受限所帶來的市場機會。
In dermatology, revenue declined by 12% for the quarter relative to the prior year as volume increases for JUBLIA and ARAZLO were offset by continued net pricing pressures and continued pressure on our nonpromoted products.
在皮膚科方面,本季營收較去年同期下滑 12%,因 JUBLIA 與 ARAZLO 的銷量增加被持續的淨價格壓力,以及我們非推廣產品持續承壓所抵銷。
And as Tom mentioned, CABTREO is launched and available for patients as of late January 2024. And in addition to the important benefits this product is expected to bring patients, we view this as an opportunity to return the dermatology business to growth.
此外,如 Tom 所提到,CABTREO 已於 2024 年 1 月下旬上市並可供患者使用。除了該產品預期可為患者帶來的重要效益之外,我們也將其視為讓皮膚科業務重回成長軌道的機會。
The generics business continues to be a profitable, cash-generative business. However, it also faces a highly competitive environment from both a pricing and volume standpoint. While it plays a role with our LOE products, with the timeline of many of those LOEs and the competitive environment we expect to face for the long term, we have revised our expectations for this business and recorded an impairment of goodwill of $91 million in the quarter.
學名藥業務仍是一項具獲利能力、可產生現金流的業務。然而,從價格與銷量角度來看,它也面臨高度競爭的環境。雖然該業務在我們 LOE 產品中扮演一定角色,但考量多項 LOE 的時間表以及我們預期長期將面對的競爭環境,我們已下修對該業務的預期,並於本季認列 9,100 萬美元的商譽減損。
Dentistry revenue of $29 million was in line with a strong fourth quarter in 2022. We continue to invest in the dentistry business for the long term and are looking to accelerate growth in 2024.
牙科業務營收為 2,900 萬美元,與 2022 年強勁的第四季表現一致。我們將持續以長期為目標投資牙科業務,並希望在 2024 年加速成長。
For the year, diversified segment revenues declined 4% on a reported basis and 3% on an organic basis relative to the prior year, with varying degrees of declines in neurology, dermatology and generics reflecting the pressures we've discussed throughout the year.
全年而言,多元化事業部營收較去年同期申報口徑下滑 4%、有機口徑下滑 3%;神經科、皮膚科與學名藥均出現不同程度的下滑,反映我們全年所討論的各項壓力。
As shown on slide 18, Bausch + Lomb revenues were $1.17 billion during the fourth quarter, up 18% on a reported basis and 7% on an organic basis compared to the prior year, with growth across all Bausch + Lomb segments. Similarly, Bausch + Lomb revenues for the year increased by $378 million on a reported basis or 10% and 8% on an organic basis compared to 2022.
如第 18 頁投影片所示,Bausch + Lomb 第四季營收為 11.7 億美元,較去年同期申報口徑成長 18%、有機口徑成長 7%,且 Bausch + Lomb 各事業部均有成長。同樣地,Bausch + Lomb 全年營收較 2022 年申報口徑增加 3.78 億美元或 10%,有機口徑成長 8%。
Turning to the fourth quarter P&L on slides 20 and 21. Fourth quarter consolidated adjusted gross margin was 71.6%, 130 basis points higher compared with the prior year. Full year consolidated adjusted gross margin was 71%, 10 basis points higher than last year.
接著看第 20 與 21 頁投影片的第四季損益表。第四季合併調整後毛利率為 71.6%,較去年同期提高 130 個基點。全年合併調整後毛利率為 71%,較去年提高 10 個基點。
For Bausch Health, excluding B&L, adjusted gross margin for the fourth quarter was 80.2%, approximately 30 basis points lower than last year's fourth quarter. For the full year, adjusted gross margin was 80.1%, a decline of 50 basis points, which included the impact of the Emerade recall earlier in the year.
就 Bausch Health(不含 B&L)而言,第四季調整後毛利率為 80.2%,較去年第四季約低 30 個基點。全年調整後毛利率為 80.1%,下滑 50 個基點,其中包含年初 Emerade 召回事件的影響。
At B&L, adjusted gross margin was 62.5% for Q4 of '23 compared to 57.9% for Q4 of 2022, driven primarily by product mix, including XIIDRA.
在 B&L,2023 年第四季調整後毛利率為 62.5%,相較 2022 年第四季的 57.9% 上升,主要由產品組合(包括 XIIDRA)所帶動。
Consolidated adjusted operating expenses for the fourth quarter were $891 million, an increase of $121 million. For Bausch Health, excluding B&L, adjusted operating expenses increased by approximately $16 million during the quarter, as higher A&P was driven by investments in the Salix segment. R&D expenses also increased primarily related to our Salix initiatives.
第四季合併調整後營業費用為 8.91 億美元,增加 1.21 億美元。就 Bausch Health(不含 B&L)而言,本季調整後營業費用約增加 1,600 萬美元,較高的 A&P 主要來自對 Salix 事業部的投資。研發費用亦增加,主要與我們的 Salix 計畫相關。
Adjusted G&A for Bausch Health, excluding B&L, was slightly favorable to the prior year, as we annualized stabilization of the post-IPO structure and focused on cost containment. B&L reported an increase of $105 million adjusted operating expenses due primarily to increased selling and A&P, driven by product launches.
Bausch Health(不含 B&L)的調整後 G&A 較前一年略為有利,因我們將 IPO 後架構穩定化的效益年化,並專注於成本控管。B&L 報告調整後營運費用增加 1.05 億美元,主要由於銷售費用及 A&P(廣告與促銷)增加,並受產品上市推動。
Consolidated adjusted R&D expense for the quarter was $151 million, an increase of 6% came to the prior year and represented 6.3% of product sales compared with 6.5% for the prior year period. For Bausch Health, excluding B&L, R&D expenses of $72 million increased by approximately $8 million for the fourth quarter as compared to the same quarter last year.
本季合併調整後研發(R&D)費用為 1.51 億美元,較前一年增加 6%,占產品銷售額的 6.3%,相較前一年同期為 6.5%。就 Bausch Health(不含 B&L)而言,研發費用為 7,200 萬美元,與去年同季相比第四季約增加 800 萬美元。
As Tom mentioned, we expect another meaningful step-up in R&D expense throughout 2024 to support the next phase of development for amiselimod. We also will continue to progress our two global RED-C Phase III clinical trials.
如 Tom 所提,我們預期 2024 年全年研發費用將再出現一次顯著上升,以支持 amiselimod 下一階段的開發。我們也將持續推進兩項全球 RED-C 第三期臨床試驗。
Fourth quarter consolidated adjusted EBITDA was $897 million, an increase of $56 million or 7% on a reported basis. Adjusted EBITDA for Bausch Health, excluding B&L, was $663 million for the quarter, a slight increase from $659 million in the fourth quarter of 2022. For the full year, consolidated adjusted EBITDA was $3.11 billion and for Bausch Health, excluding B&L, was $2.36 billion, both slight increases from '22.
第四季合併調整後 EBITDA 為 8.97 億美元,按報告基礎增加 5,600 萬美元或 7%。Bausch Health(不含 B&L)本季調整後 EBITDA 為 6.63 億美元,較 2022 年第四季的 6.59 億美元小幅增加。全年合併調整後 EBITDA 為 31.1 億美元;Bausch Health(不含 B&L)為 23.6 億美元,兩者皆較 2022 年小幅增加。
Turning to cash flow. On a consolidated basis, Bausch Health generated $390 million of operating cash flow and $305 million of adjusted operating cash flow in the fourth quarter. Full year cash flow from operations on a consolidated basis was $1.03 billion and adjusted cash flow from operations on a consolidated basis was $763 million.
接著談現金流。以合併基礎計,Bausch Health 第四季產生營運現金流 3.90 億美元,以及調整後營運現金流 3.05 億美元。全年合併基礎的營運活動現金流為 10.3 億美元,合併基礎的調整後營運活動現金流為 7.63 億美元。
For Bausch Health, excluding B&L, adjusted operating cash flow was $278 million for the fourth quarter and $708 million for the full year compared to adjusted operating cash flow of $340 million for the fourth quarter of '22 and $637 million for the full year 2022, with the changes primarily reflecting the timing of working capital movements and for Q4, the timing of interest payments.
就 Bausch Health(不含 B&L)而言,第四季調整後營運現金流為 2.78 億美元,全年為 7.08 億美元;相較之下,2022 年第四季為 3.40 億美元、2022 年全年為 6.37 億美元。變動主要反映營運資金變動的時點差異,以及就第四季而言,利息支付時點的影響。
The full year 2023 also exceeded our guidance of $625 million, driven by our focus on expense management as well as by the timing of cash collections based on the wholesaler buying patterns I discussed earlier.
2023 年全年亦超出我們 6.25 億美元的指引,主要受我們對費用管理的專注所帶動,亦受我先前提到、基於批發商採購模式而產生的現金回收時點影響。
As we've discussed in prior quarters, as a result of the accounting treatment for the senior notes issued as part of our 2022 debt exchange, a portion of our cash interest payments are classified as financing cash flows. Adjusted cash flow includes payments of the full contractual interest as well as adjustments for the payment of separation costs, business transformation costs, and litigation and other matters, net of insurance proceeds.
如我們在先前季度所討論,由於對作為 2022 年債務交換一部分所發行之優先票據的會計處理,我們部分現金利息支付被分類為籌資活動現金流。調整後現金流包含全額合約利息的支付,並就分拆成本、業務轉型成本,以及訴訟與其他事項(扣除保險理賠收入)進行調整。
Now let's turn to our balance sheet on slide 22. We continued to prioritize liquidity management and the delevering of our balance sheet. In the fourth quarter of 2023, we reduced our debt net of cash for Bausch Health, excluding B&L, by approximately $250 million. We continue to evaluate alternatives to reduce our overall leverage while also focusing on our maturity profile.
現在請看第 22 頁投影片的資產負債表。我們持續將流動性管理與降低資產負債表槓桿列為優先事項。在 2023 年第四季,我們將 Bausch Health(不含 B&L)的淨負債(扣除現金)降低約 2.50 億美元。我們持續評估降低整體槓桿的替代方案,同時也聚焦於到期結構。
Despite only retiring a small amount of debt in Q4, in January 2024, we retired $250 million in principal value of 2025 and 2026 maturities through open market repurchases, capturing approximately $12 million of discount in the process.
儘管第四季僅償還少量債務,但在 2024 年 1 月,我們透過公開市場回購,償還了 2025 年與 2026 年到期債務本金面額 2.50 億美元,並在過程中取得約 1,200 萬美元的折價收益。
At the end of the fourth quarter, Bausch Health, excluding B&L, had $350 million outstanding under our accounts receivable facility and had no outstanding borrowings and approximately $950 million of availability under our revolving credit facility.
截至第四季末,Bausch Health(不含 B&L)在應收帳款融資安排下尚有 3.50 億美元未償餘額,循環信貸額度下無未償借款,且可動用額度約 9.50 億美元。
As shown on slides 23 and 24, total debt for Bausch Health, excluding Bausch + Lomb, at the end of the quarter was $16.4 billion, which consisted of approximately $15 billion of restricted debt issued by Bausch Health, excluding B&L, and approximately $1.4 billion of unrestricted debt, which includes the $1 billion of senior secured notes issued by the unrestricted subsidiary created in the third quarter of 2022 and the $350 million drawn under our accounts receivable facility.
如第 23 與 24 頁投影片所示,截至本季末,Bausch Health(不含 Bausch + Lomb)的總負債為 164 億美元,其中約 150 億美元為由 Bausch Health(不含 B&L)發行的受限制債務,約 14 億美元為不受限制債務;不受限制債務包含 2022 年第三季設立之不受限制子公司所發行的 10 億美元優先擔保票據,以及在我們的應收帳款融資安排下提取的 3.50 億美元。
Excluding B&L debt, approximately 85% of our debt is fixed and approximately 70% of the company's debt on a consolidated basis is fixed. Debt, net of cash for Bausch Health, excluding B&L, is down approximately $670 million since the beginning of 2023.
不含 B&L 債務,我們約 85% 的債務為固定利率;以合併基礎計,公司約 70% 的債務為固定利率。自 2023 年初以來,Bausch Health(不含 B&L)的淨負債(扣除現金)已下降約 6.70 億美元。
We ended the year with over $1.5 billion of liquidity, including approximately $616 million of cash and $950 million of availability under our revolving credit facility. We will continue to evaluate the best uses of that liquidity, including focus on our maturity profile and our overall leverage.
我們在年底的流動性超過 15 億美元,其中包含約 6.16 億美元現金,以及循環信貸額度下 9.50 億美元的可動用額度。我們將持續評估該等流動性的最佳用途,包括聚焦於到期結構與整體槓桿水準。
Overall, we are pleased that revenues, adjusted EBITDA, and adjusted operating cash flow for 2023 for Bausch Health, excluding B&L, met or exceeded expectations. With that as the backdrop, I'll now discuss our guidance for 2024, which you can find on slide 26.
整體而言,我們很高興 Bausch Health(不含 B&L)2023 年的營收、調整後 EBITDA 與調整後營運現金流符合或超出預期。在此背景下,我接著將說明我們 2024 年的指引,您可在第 26 頁投影片找到。
In 2024, we expect revenues of $4.7 billion to $4.85 billion, with growth of 2% to 5% on an organic basis. For 2024, we expect foreign exchange impact to be a slight tailwind. Full year adjusted EBITDA for Bausch Health, excluding B&L, is expected to be $2.36 billion to $2.46 billion.
2024 年,我們預期營收為 47 億至 48.5 億美元,有機成長 2% 至 5%。就 2024 年而言,我們預期外匯影響將帶來些微順風。Bausch Health(不含 B&L)全年調整後 EBITDA 預期為 23.6 億至 24.6 億美元。
For Salix, we expect to see mid-single-digit revenue growth. Based on the investments we've made, we expect volume growth from a TRx and extended unit perspective to expand relative to what we saw in 2023, although changes in wholesaler purchasing dynamics may temper how that growth translates into revenue growth. We also intend to maintain our investments in selling and A&P consistent with 2023 levels.
就 Salix 而言,我們預期營收將呈現中個位數成長。基於我們已進行的投資,我們預期從 TRx 與延伸單位(extended unit)的角度,量的成長將較 2023 年所見有所擴大;然而,批發商採購動態的變化可能會抑制該成長轉化為營收成長的幅度。我們也打算維持對銷售與 A&P(廣告與促銷)的投資,與 2023 年水準一致。
Lastly, as we've noted in the past, we typically see a seasonal step-up in sales in the second half, particularly in XIFAXAN, primarily due to wholesaler inventory dynamics as well as patient level patterns related to insurance deductible activity.
最後,如我們過去所提,我們通常會在下半年看到銷售的季節性上升,尤其是在 XIFAXAN,主要由於批發商庫存動態,以及與保險自付額(deductible)活動相關的病患端模式。
For international, we expect mid-single-digit organic revenue growth, led by the EMEA and Latin America regions. We are excited by the potential for new product launches in these regions. In Canada, we plan to further grow the recently launched products, RYALTRIS and UCERIS and continue to focus on obtaining approval of CABTREO. We're also making targeted investments in sales teams and promotion across the different regions.
就國際市場而言,我們預期有機營收將呈現中個位數成長,主要由 EMEA 與拉丁美洲地區帶動。我們對這些地區新產品上市的潛力感到振奮。在加拿大,我們計畫進一步成長近期上市的產品 RYALTRIS 與 UCERIS,並持續聚焦取得 CABTREO 的核准。我們也正在各地區針對性地投資銷售團隊與推廣活動。
For Solta, we anticipate strong double-digit organic revenue growth across all major geographies. We have new leaders in key positions in this business and have invested in expansion of the US sales team. Therefore, we anticipate growth led by China and Asia Pacific as well as double-digit growth in the US and EMEA regions.
就 Solta 而言,我們預期在所有主要地理區域皆將出現強勁的雙位數有機營收成長。我們在此業務的關鍵職位已任命新的領導團隊,並已投資擴編美國銷售團隊。因此,我們預期成長將由中國與亞太地區帶動,同時美國與 EMEA 地區亦將呈現雙位數成長。
For Diversified, we expect an overall mid-single-digit decline in organic revenue. We expect growth in dermatology led by the introduction of CABTREO and in dentistry, driven by continued investment in the sales force and related tools, with continued pressures in our neurology and generics businesses.
就 Diversified 而言,我們預期整體有機營收將中個位數下滑。我們預期皮膚科將在 CABTREO 導入帶動下成長,牙科則受持續投資銷售人力與相關工具所驅動而成長;同時,我們的神經科與學名藥業務仍將面臨持續壓力。
From a gross margin perspective, we expect to continue to mitigate the impact of inflation on our cost of goods sold, and we expect our gross margin to remain comparable to last year at approximately 80%.
從毛利率的角度來看,我們預期將持續減輕通膨對銷貨成本的影響,並預期我們的毛利率將與去年大致相當,約為80%。
On the expense side, we anticipate that selling and A&P will grow in line with sales growth, as we maintain the base we established in 2023 and make targeted investments to drive growth in businesses, including Solta and dentistry.
在費用端,我們預期銷售與A&P將隨銷售成長同步增加,因為我們將維持2023年建立的基礎,並進行有針對性的投資以推動業務成長,包括Solta與牙科。
Additionally, as we've discussed previously, there will be a meaningful increase in R&D spend throughout the year, as we invest for the future in our GI and aesthetics pipeline programs. We think it is critical to continue to allocate capital to this area for the long term, as it will benefit patients and health care providers while positioning our business to deliver stakeholder value.
此外,正如我們先前討論過的,全年研發支出將出現顯著增加,因為我們將為未來投資於我們的腸胃(GI)與醫美管線計畫。我們認為,從長期來看持續將資本配置於此領域至關重要,因為這將使病患與醫療照護提供者受益,同時讓我們的業務具備為利害關係人創造價值的定位。
Lastly, we expect adjusted operating cash flow for Bausch Health, excluding B&L, in a range of approximately $775 million to $825 million for 2024. And as I said earlier, adjusted cash flow includes adjustments for the payment of separation costs, the payment of the full contractual interest on our existing debt, and also includes lower tax payments in 2024 relative to 2023, inclusive of the impact of the tentative Granite Trust Settlement.
最後,我們預期2024年Bausch Health(不含B&L)的調整後營運現金流將約落在7.75億至8.25億美元之間。如我先前所說,調整後現金流包含對分拆成本支付的調整、對現有債務全額合約利息的支付,並且也包含2024年相較於2023年較低的稅款支付,其中納入暫定的Granite Trust和解之影響。
I'll now hand the call back to Tom.
我現在把電話交回給Tom。
Thomas Appio - CEO
Thomas Appio - CEO
Thank you, John. In summary, as you heard today, we made significant progress against our 2023 strategic priorities, and we enter 2024 with strong momentum and a clear set of objectives. We are excited about the potential of our Salix business led by XIFAXAN, and we will continue to advance our pipeline with RED-C and amiselimod. We believe Solta is poised for long-term growth with Thermage FLX in China and untapped potential in the US and EMEA.
謝謝你,John。總結來說,正如各位今天所聽到的,我們在2023年的策略優先事項上取得了重大進展,並以強勁動能與明確目標邁入2024年。我們對以XIFAXAN為主導的Salix業務潛力感到振奮,並將持續推進RED-C與amiselimod的研發管線。我們相信Solta在中國的Thermage FLX以及美國與EMEA尚未開發的潛力帶動下,已具備長期成長的有利態勢。
The broad portfolio of products and geographies in our international business will continue to provide balanced growth. And in our diversified business, we believe dermatology with the launch of CABTREO, and dentistry will deliver growth, with the remainder of the portfolio remaining profitable and cash generative in a challenging, competitive and regulatory environment.
我們國際業務涵蓋廣泛的產品組合與地理市場,將持續提供均衡成長。而在我們的多元化業務中,我們相信皮膚科(隨CABTREO上市)與牙科將帶來成長;在充滿挑戰、競爭激烈且監管嚴格的環境下,其餘產品組合仍將維持獲利並產生現金。
For the year ahead, we are focused on building on the foundation we have set across our diverse global business by driving a results-oriented culture of accountability; delivering on our revenue, adjusted EBITDA, and adjusted operating cash flow commitments; executing with operational excellence and cost-focused mindset across the enterprise; intensifying our focus and operating rigor behind R&D and business development; and continuing to evaluate strategic alternatives.
展望未來一年,我們將專注於在多元的全球業務上,延續既有基礎並推動以成果為導向的問責文化;達成我們對營收、調整後EBITDA與調整後營運現金流的承諾;以卓越營運與成本導向的思維在全企業落實執行;加強對研發與業務發展的聚焦與營運紀律;並持續評估策略替代方案。
We will execute against these objectives with a focus on operational excellence with a patient-centered mentality.
我們將以病患為中心的心態,聚焦卓越營運來落實這些目標。
I am thankful for and proud of our Bausch Health team for their achievements this year. They have worked tirelessly and are all in to position our business for the long term.
我對Bausch Health團隊今年的成就心懷感謝並深感自豪。他們不懈努力,全力以赴,為我們的業務長期發展做好定位。
Life won't wait, neither can we. Every patient deserves better health and the chance to make the most of life. This drives us on with urgency and efficiency to deliver the products patients need most to enrich their lives.
生命不會等待,我們也不能等待。每位病患都值得擁有更好的健康,以及把握人生的機會。這驅使我們以更高的急迫感與效率,提供病患最需要的產品,豐富他們的生活。
On behalf of our entire Bausch Health team, I thank you for your interest in and support of our company. With that, we will now take questions. Operator, please open the line for Q&A.
我謹代表整個Bausch Health團隊,感謝各位對本公司的關注與支持。接下來我們將開始提問。接線員,請開放問答。
Operator
Operator
(Operator Instructions) Glen Santangelo, Jefferies.
(接線員指示) Jefferies的Glen Santangelo。
Glen Santangelo - Analyst
Glen Santangelo - Analyst
Thanks for taking my questions. Hey, Tom, I just had two quick ones. I appreciate all the details on the two pipeline programs, but as we think about doing some long-term modeling, I was wondering if you could maybe help us think about broad timelines for both these programs as we think about the path to approval.
謝謝讓我提問。嗨,Tom,我只有兩個簡短問題。我很感謝你們對兩個研發管線計畫提供的所有細節,但當我們思考做一些長期模型推估時,我想請你或許能協助我們思考這兩個計畫在走向核准路徑上的大致時間表。
And then maybe secondly, in recent quarters, I mean, the company has talked about a number of different recapitalization opportunities. And in your prepared remarks, you talked about how you retired $250 million of debt in January. And I was just sort of wondering, given where the debt is trading, where BLCO is trading, given that Solta is doing much better. Without getting specific, do you see any meaningful opportunities for further recapitalization efforts in 2024? And I'll stop there. Thanks.
第二點,最近幾個季度,公司談到過多種不同的資本重整機會。而在你們的事先準備發言中,你提到你們在1月償還了2.5億美元的債務。我只是想問,在目前債務的交易價格、BLCO的交易價格,以及Solta表現明顯更好的情況下,在不談具體細節的前提下,你是否看到2024年進一步推動資本重整的任何重大機會?我就問到這裡。謝謝。
Thomas Appio - CEO
Thomas Appio - CEO
Glen, thanks. Appreciate the question. So overall, when we take a look at these two programs, clearly, if we take a look at RED-C, we think this is a great opportunity. Clearly, the patient pool here is large, much bigger than today's patient pool that we're looking at because this is a prevention trial.
Glen,謝謝。感謝你的提問。整體而言,當我們檢視這兩個計畫時,顯然若看RED-C,我們認為這是一個很好的機會。很明顯,這裡的病患族群很大,遠大於我們今天所看到的病患族群,因為這是一項預防性試驗。
So as we -- one of the things that we did this year was really energize and put more money behind those studies to make sure we got the recruitment. As I said in my prepared remarks, we had the one study completely recruited. And then the second study, we're expecting that in the first half.
因此,當我們——今年我們做的一件事,就是真正為這些研究注入動能並投入更多資金,以確保我們完成受試者招募。如我在事先準備的發言中所說,其中一項研究已完成全部招募。而第二項研究,我們預期將在上半年完成。
So trying to really accelerate that program, so we have a launch probably in some time in 2027. This is going to be, again, a large pool. It is prevention. So clearly, there's a good -- really good opportunity for us.
因此我們正努力加速該計畫,讓我們可能在2027年的某個時間點推出上市。這同樣將是一個龐大的族群。它是預防性用途。因此,對我們而言顯然是一個非常好的機會。
On the amiselimod side, of course, we are really pleased with the data on the Phase II program. These were -- this was a very large Phase II program. We're working right now to see what the timing will be of the Phase III program. We're expecting at the end of the decade to be able to launch the product in UC.
至於amiselimod方面,當然,我們對第二期(Phase II)計畫的數據非常滿意。這是一個非常大型的第二期計畫。我們目前正在評估第三期(Phase III)計畫的時間安排。我們預期在本十年末能夠在潰瘍性結腸炎(UC)適應症推出該產品。
As I said in my prepared remarks, there is an opportunity here to continue to expand as if we looked at Crohn's and running a Phase II program and then if the data is good, clearly running a Phase III program, which would push approval something into the first half of the next decade.
如我在事先準備的發言中所說,這裡也有機會持續擴展;例如若我們著眼於克隆氏症並進行第二期計畫,若數據良好,顯然可再進行第三期計畫,這將使核准時間推進到下一個十年的上半段。
So I really think these two programs give us a really good momentum on our R&D programs as we look forward. When I'll turn off -- turn the call over to -- the question over to John to talk about the debt.
因此,我確實認為這兩個計畫在我們展望未來時,為研發計畫帶來非常好的動能。接下來我把——把這個問題交給John來談債務。
John Barresi - Interim CFO
John Barresi - Interim CFO
Yeah. Thanks, Glen. Yeah, as we've said, we're always looking at the options that we have to manage our balance sheet, manage our debt. We're not going to comment on any specific strategies or actions that we may undertake at any point in the future. But what I will say is if you think about where we sit today, we have over $1.5 billion of liquidity between our cash and the revolver flexibility.
好的。謝謝,Glen。是的,正如我們所說,我們一直在尋找可用的選項來管理資產負債表、管理債務。我們不會評論未來任何時間點可能採取的具體策略或行動。但我想說的是,若你看我們目前的位置,我們在現金與循環信貸額度的彈性之間,擁有超過15億美元的流動性。
We're guiding to $775 million to $825 million of adjusted operating cash flow, and we typically use a fair amount of that to manage our debt. As you noted, we do have the flexibility on the roughly 8% of BLCO that we still own that we have the option to monetize at some point and we are focused on reducing debt. So we're always looking at all the tools and all the options, but we're not going to comment on anything specifically at this point.
我們給出的指引是調整後營運現金流為7.75億至8.25億美元,而我們通常會將其中相當一部分用於管理債務。如你所提到,我們對仍持有約8%的BLCO具備彈性,可在某個時間點選擇變現,而我們也專注於降低債務。因此我們一直在檢視所有工具與選項,但目前不會對任何具體事項作出評論。
Operator
Operator
David Amsellem, Piper Sandler.
Piper Sandler的David Amsellem。
Unidentified Participant
Unidentified Participant
Hi, this is [Skylar] on for David. So first, what are your thoughts on how amiselimod could fit into the UC space in the context of existing approved S1Ps and a pretty competitive pipeline? And then separately, could you also talk about the extent to which you will further invest in XIFAXAN as it moves through the later part of its commercial life? Thanks.
嗨,我是代替 David 的 [Skylar]。首先,在既有已核准的 S1P 藥物以及相當具競爭性的研發管線背景下,您怎麼看 amiselimod 在潰瘍性結腸炎(UC)領域可能扮演的角色?另外,也請談談隨著 XIFAXAN 進入其商業生命週期後段,您將在多大程度上持續加碼投資?謝謝。
Thomas Appio - CEO
Thomas Appio - CEO
What I would say is on amiselimod, clearly, among the S1Ps, the positive top line data suggests it could be a promising therapy in terms of efficacy and safety in the space. There are a few others in this space when we look at the data. We think we have a real competitive product here.
我會說,就 amiselimod 而言,很明顯地,在 S1P 類藥物中,正向的主要(top-line)數據顯示,它在此領域的療效與安全性方面可能是一個很有前景的治療選項。當我們看數據時,這個領域還有其他幾個產品。我們認為我們在這裡有一個真正具競爭力的產品。
So as we continue to really look at the data and build our Phase III program, we'll see where that sits. But we think, again, on the positive top-line data, it looks really good.
因此,隨著我們持續深入檢視數據並建立第三期(Phase III)計畫,我們會再看它的位置會落在哪裡。但我們認為,再次強調,從正向的主要數據來看,表現看起來非常好。
What I would say is on XIFAXAN, we have multiple formulations on XIFAXAN. We're always looking from an R&D perspective of where we could use these new formulations as the RED-C program. Clearly, we're using one of our new formulations, but we're always looking for and looking at the link between the gut and the brain. And then clearly, that is a focus for the team.
至於 XIFAXAN,我會說我們有多種 XIFAXAN 的劑型。從研發角度,我們一直在尋找這些新劑型可用於哪些地方,例如 RED-C 計畫。很明顯地,我們正在使用其中一個新劑型,但我們也一直在尋找並關注腸道與大腦之間的連結。而這顯然也是團隊的重點方向。
When I talk about investing in XIFAXAN on the commercial life side of it, I still think even though XIFAXAN is late in its life cycle, as you saw the results for 2023, they are strong. We believe we can continue to grow our franchise, the investments we have put behind, AI for the field force and that has been rolled out to the entire -- the field force on both the primary care and specialty care side.
當我談到在商業生命週期面向對 XIFAXAN 的投資時,我仍然認為,即使 XIFAXAN 已處於生命週期後段,如你們在 2023 年看到的結果,表現依然強勁。我們相信可以持續擴大我們的產品事業群;我們已投入的投資包括為業務團隊導入 AI,而且已全面推廣到整個——無論是基層醫療(primary care)或專科醫療(specialty care)的業務團隊。
If you look at the data that we saw in the fourth quarter as we exited the year, the data was strong. And so that -- those tools are really going to help us move forward with XIFAXAN. The other thing also is, when I take a look at XIFAXAN, clearly, there's a lot of unmet need still there, and I think we can tap that with the programs and the investments that we're making between AI and DTC, as I said in my prepared remarks.
如果你看我們在第四季、年底時所看到的數據,數據很強。因此——這些工具確實會幫助我們推動 XIFAXAN 往前走。另外一點是,當我看 XIFAXAN 時,很明顯地仍有大量未被滿足的醫療需求;我認為我們可以透過正在進行的計畫與投資來切入這些需求,包括 AI 與 DTC(直接面向消費者),正如我在事先準備的發言中提到的。
I really -- the team has really done a really great job this year with XIFAXAN and getting -- putting -- getting the growth on it and then the unmet need that is still there in both the IBS-D side of the business and the AG side of the business, there's still an unmet need that we can treat more patients.
我真的——團隊今年在 XIFAXAN 上做得非常出色,推動——帶動——實現了成長;而且在 IBS-D 業務與 AG 業務兩端,仍存在未被滿足的需求,我們還能治療更多病患。
Operator
Operator
Umer Raffat, Evercore ISI.
Umer Raffat,Evercore ISI。
Unidentified Participant
Unidentified Participant
Hi. This is [Chanse Topher] on for Umer. Thanks for taking our questions. Two questions, if I may. So first, in a scenario that Norwich loses the patent appeal, will they reignite their APA loss case deal? And if that -- if so, what would be the angle? And secondly, can we get more color on the [SGN] increase in the fourth quarter and your expectation in 2024? Thank you.
嗨。我是代替 Umer 的 [Chanse Topher]。謝謝回答我們的問題。如果可以的話兩個問題。第一,在 Norwich 輸掉專利上訴的情境下,他們是否會重新啟動他們的 APA(依《行政程序法》)「敗訴」案件和解?如果會,切入點會是什麼?第二,能否請你們多談談第四季 [SGN] 增加的原因,以及你們對 2024 年的預期?謝謝。
Thomas Appio - CEO
Thomas Appio - CEO
Could you just -- on the first part of your question, what specifically you're asking on Norwich? Just could you -- trying -- I'm trying to understand what you're actually asking there.
你能不能——就你問題的第一部分,你具體想問 Norwich 的哪一點?你能不能——我想——我想更清楚你實際在問什麼。
Unidentified Participant
Unidentified Participant
Let me repeat. So if in a scenario that Norwich loses the patent of your case, will they reignite their APA against the FDA case? If so, what will be the angle?
我再重複一次。如果在 Norwich 輸掉你們的專利案件的情境下,他們是否會重新點燃他們對 FDA 提起的 APA 訴訟?如果會,會採取什麼角度?
Thomas Appio - CEO
Thomas Appio - CEO
Yeah. I can't comment on what they would do on their litigation if they were to lose. So I mean, again, I can't comment on the call of what their steps would be. But again, we feel confident in our appeal and in our intellectual property.
是的。如果他們敗訴,我無法評論他們在訴訟上會怎麼做。所以我的意思是,我同樣無法評論他們接下來會採取哪些步驟。但我們對我們的上訴以及我們的智慧財產權仍然有信心。
Operator
Operator
Jason Gerberry, Bank of America.
Jason Gerberry,美國銀行(Bank of America)。
Unidentified Participant
Unidentified Participant
Hi. This is [Chi] on for Jason. Thanks for taking our question. A couple from us. So regarding the XIFAXAN appeal decision that you expect later in first quarter, early second quarter, say, let's say the appeal is favorable to Bausch, how does the favorable appeal ruling impact your thinking on the separation of BLCO? Would you look to move quickly once the particular legal matter is resolved? Or are there other settlements in legal matters contingent?
嗨。我是代替 Jason 的 [Chi]。謝謝回答我們的問題。我們有幾個問題。關於你們預期在第一季末、第二季初出爐的 XIFAXAN 上訴裁決,假設上訴結果對 Bausch 有利,這樣的有利裁定會如何影響你們對 BLCO 分拆的思考?一旦特定法律事項解決後,你們會考慮加快推進嗎?還是還有其他法律事項的和解是具條件性的?
And my second question is on amiselimod. You ran a Phase II in mild to moderate, and it sounds like you are moving -- thinking about moving Phase III to in a moderate-to-severe population. So I'm curious what prompt that change? And given there are multiple other S1Ps already approval in development in the moderate or moderate-to-severe population?
第二個問題是關於 amiselimod。你們在輕至中度患者做了第二期(Phase II),聽起來你們正在——考慮把第三期(Phase III)轉向中度至重度族群。我想了解是什麼促使這個改變?而且考量到在中度或中度至重度族群中,已經有多個其他 S1P 藥物獲批或正在開發?
Thomas Appio - CEO
Thomas Appio - CEO
Okay. On your first part of the question regarding XIFAXAN, what I would say is this is, as you know, we had the appeal that was heard, the oral arguments were heard in January. We believe it went well. What I would say is we believe that the -- if we were to win, there are still factors that we need to consider. We believe that the separation continues to make strategic sense. And there are many factors that will go into the timing of any potential distribution, and there's no committed time line at this time.
好的。就你第一部分關於 XIFAXAN 的問題,我會說,如你所知,我們的上訴已經開庭審理,口頭辯論在一月已進行。我們認為進展良好。我會說的是,我們認為——即便我們勝訴,仍有一些因素需要考量。我們相信分拆在策略上仍然合理。任何潛在分派(distribution)的時點會受到許多因素影響,目前尚未有承諾的時間表。
What I would say on amiselimod, when we look at the data and the positive data that we saw, as you know, we ran the trial mild to moderate, we think that amiselimod has the potential to be very broad in what the data shows.
至於 amiselimod,當我們看數據以及我們看到的正向結果時,如你所知,我們的試驗是在輕至中度族群進行;我們認為從數據所呈現的結果來看,amiselimod 的潛在適用範圍可以非常廣。
So we did -- when the trial was running, we did have mild to moderate. But as we look at it, we can move it more into moderate to severe on a Phase III program. And as I said in my prepared remarks, probably treat all, but that's still under discussion.
所以我們確實——在試驗進行時,我們納入的是輕至中度。但當我們再看這些結果時,我們可以在第三期計畫中把它更往中度至重度推進。而且如我在事先準備的發言中所說,可能會涵蓋所有患者,但這仍在討論中。
Operator, next question.
接線員,下一個問題。
Operator
Operator
Douglas Miehm, RBC Capital Markets.
Douglas Miehm,RBC 資本市場(RBC Capital Markets)。
Douglas Miehm - Analyst
Douglas Miehm - Analyst
Great. Thank you. Question has to do with Q4 of XIFAXAN and Trulance where it looked like it was a little flat. And forgive me if you spoke about this already. Just curious as to why that occurred given the strong prescription strength during the quarter and also the pricing increase you took at the beginning of the year.
很好。謝謝。我的問題與 XIFAXAN 和 Trulance 的第四季有關,看起來有點持平。如果你們已經談過這點也請見諒。我只是好奇,考量到該季處方量(prescription)表現強勁,以及你們在年初也做了提價,為什麼會出現這種情況?
And then perhaps related to that, you can expand on the commentary that was made around prescription growth in the guidance, 2024? And how that could be impacted by, I think it was managed care that you talked about? Thank you.
然後也許與此相關,你們能否延伸說明一下在 2024 年指引中提到的處方成長評論?以及它可能會如何受到你們提到的——我想是受管理式醫療(managed care)影響?謝謝。
Thomas Appio - CEO
Thomas Appio - CEO
Yes. So let me just overall, when I -- when we look at XIFAXAN and the TRx growth, if you look at the product for the full year, we had an increase of 8%, 3% on price, 5% on volume, and we talked about some of the inventory channels, the inventory channel that we had.
好的。所以我先整體說明,當我——當我們看 XIFAXAN 以及 TRx 成長時,如果你看全年產品表現,我們成長了 8%,其中 3% 來自價格、5% 來自量,另外我們也談到一些庫存通路(inventory channels)——我們所涉及的庫存通路。
But overall, the TRx growth that we looked at it for the year was strong. And when we looked at the fourth quarter, on the IBS-D side, we were exiting at much higher than what the full year looked like.
但整體而言,我們觀察到今年的 TRx 成長表現強勁。而當我們看第四季時,在 IBS-D 方面,我們在季末的水準遠高於全年平均所呈現的水準。
And when we look at HE in the long-term care space, that was over 6%. So the product as the performance -- as we ramped up the investments, okay, and launched different activities during the year, you could see it benefited from the second half.
而當我們看長期照護領域的 HE 時,成長超過 6%。因此,就產品表現而言——隨著我們加大投資、並在一年中推出不同活動,你可以看到它受惠於下半年。
I'll let John talk specifically about your second part of question.
我會讓 John 針對你問題的第二部分做更具體的說明。
John Barresi - Interim CFO
John Barresi - Interim CFO
Yeah. On the revenue trends, if you remember in the third quarter, Salix was plus 13%, I believe, for the third quarter. And we saw -- at this time, we spoke about some pull forward of the demand increase that we'd normally see in Q4 into the later stages of Q3. And so that, I think, is the biggest driver of the difference between revenue growth and TRx growth for Q4 on the XIFAXAN and the Trulance side.
好的。就營收趨勢而言,如果你還記得第三季,Salix 在第三季成長約 13%。而我們也看到——當時我們提到,原本通常會在第四季出現的需求增加,有一部分被提前到第三季後段。因此,我認為這是第四季在 XIFAXAN 與 Trulance 方面,營收成長與 TRx 成長之間差異的最大驅動因素。
And then on the question of the Q4 guidance, I think what we had said was we expect expansion of the growth of TRx. However, we did end 2023, a little bit higher in the wholesale channel than we ended 2022. And so we had a little bit of a build there.
接著關於第四季指引的問題,我想我們當時說的是,我們預期 TRx 的成長會擴大。不過,我們在 2023 年底於批發通路的庫存水位,確實比 2022 年底略高一些。因此那裡有一點點的累積。
And it's possible, right? The wholesalers have their own algorithms for how and when they buy, but it's possible that if we see that revert back a little that it could temper some of the benefit from a revenue standpoint of the underlying demand growth.
而這是有可能的,對吧?批發商有他們自己的演算法來決定何時以及如何採購,但如果我們看到其回落一些,從營收角度來看,可能會削弱部分由基礎需求成長所帶來的效益。
Thomas Appio - CEO
Thomas Appio - CEO
Lastly, when we just take a look at it, we could frame it, when we look at IBS-D, there's 2.2 million patients that are diagnosed, but only about 140,000 received treatment, so again, with a second-line medication like XIFAXAN. So clearly, still a large unmet need and some of the investments that we have made this year and last year, and we will continue to make in 2024 to capture that.
最後,當我們簡單看一下並加以框架化:在 IBS-D 方面,有 220 萬名患者被診斷出來,但只有約 14 萬人接受治療,也就是使用像 XIFAXAN 這樣的第二線用藥。因此很明顯仍有很大的未被滿足需求,而我們今年與去年所做的一些投資,以及我們在 2024 年將持續投入的投資,都是為了掌握這個機會。
On the HE side, if you look at the analytics that we look at, there's about 190,000 patients that potentially have HE and only 50,000 approximately are treated with XIFAXAN, which is the standard of care and the only approved medication for HE. So again, large unmet need that we're going to continue to invest behind.
在 HE 方面,如果你看我們所使用的分析數據,大約有 19 萬名患者可能患有 HE,但只有約 5 萬人使用 XIFAXAN 治療;XIFAXAN 是標準治療,也是唯一獲核准用於 HE 的藥物。因此同樣地,仍有很大的未被滿足需求,我們將持續加大投資。
Operator, next question.
接線員,下一個問題。
Operator
Operator
Michael Nedelcovych, TD Cowen.
TD Cowen 的 Michael Nedelcovych。
Michael Campbell - Analyst
Michael Campbell - Analyst
Thank you for the question. I have two. For the first, if you could transport us to late May, let's assume that you had a wildly favorable ruling in the case against Norwich, such that XIFAXAN exclusivity out to 2028 is all but certain.
謝謝你的回答。我有兩個問題。第一個,如果你能帶我們回到 5 月下旬,假設你們在對 Norwich 的案件中獲得極為有利的裁決,使得 XIFAXAN 的獨占權延續到 2028 年幾乎已成定局。
I know that as it relates to the Bausch + Lomb full separation, there are multiple additional factors to consider. But what is item number two on your checklist? So the XIFAXAN ruling is done and its outlook is certain. What's item number two when you move towards full separation?
我知道就 Bausch + Lomb 的完全分拆而言,還有多個額外因素需要考量。但你們清單上的第二項是什麼?也就是說,XIFAXAN 的裁決已定且前景確定。當你們朝向完全分拆推進時,第二項是什麼?
And then my second question relates to amiselimod. Has already been noted, there are two other S1P receptor modulators approved for UC, but their market reception so far has been lukewarm. Do you think that amiselimod has better commercial prospects than the agents already approved? And if so, why is that?
第二個問題與 amiselimod 有關。如先前已提到,目前已有兩個 S1P 受體調節劑獲核准用於 UC,但迄今市場反應偏冷淡。你認為 amiselimod 的商業前景會比已核准的藥物更好嗎?如果是,原因是什麼?
Thomas Appio - CEO
Thomas Appio - CEO
Yes. So let's take the first part of the question. I can't speculate on what number two would be. There's -- as I said, there are still many factors that go into the timing of the potential distribution. And clearly, again, we believe in our intellectual property and hoping for a favorable outcome. But there are a multitude of steps. So I can't speculate on what number two would be but clearly looking to a favorable outcome on the XIFAXAN case.
是的。我們先回答第一部分。我無法推測第二項會是什麼。正如我所說,潛在分配時點仍有許多因素會影響。而且很明確地,我們相信我們的智慧財產權,也希望能有有利的結果。但其中有許多步驟。因此我無法推測第二項會是什麼,但很明顯我們期待 XIFAXAN 案件能有有利結果。
When it comes to amiselimod, we've had a lot of discussions on this internally. Yes, the two that are out there are, as you use lukewarm. We believe based on our data that we have a competitive product, a once-a-day treatment and oral.
至於 amiselimod,我們內部已經進行了很多討論。是的,市面上的那兩個產品,正如你所說,反應偏冷淡。我們相信,根據我們的數據,我們有具競爭力的產品:每日一次、且為口服治療。
So clearly, we -- as we continue to look at it and build the Phase III program, I can give you more information as we move forward in -- on the program and see what we think going forward. But when we look at our data, again, we think it's positive, and we think we have a really interesting product here.
因此很明顯,我們——隨著持續評估並建立第三期計畫,我可以在我們推進該計畫、並看到我們對未來的看法時,提供更多資訊。但就我們目前的數據來看,我們再次認為結果是正面的,也認為這是一個非常有意思的產品。
Operator, next question.
接線員,下一個問題。
Operator
Operator
Thank you very much. Well, that appears to be the last of our questions. I will now hand back over to Tom for any closing comments.
非常感謝。看起來這就是我們最後一個問題。我現在把時間交還給 Tom,請他做任何結語。
Thomas Appio - CEO
Thomas Appio - CEO
Okay. Well, since there's no further comments, I want to say thank you to all who joined the call today. As we discussed on this call, we had a solid Q4 and 2023. We grew our company and delivered or exceeded our guidance.
好的。既然沒有其他意見,我想對今天參與電話會議的各位致謝。如我們在本次電話會議中所討論的,我們第四季與 2023 年表現穩健。我們推動公司成長,並達成或超越我們的指引。
I would like to thank my over 7,000 colleagues around the world for their relentless draw to deliver better health outcomes and continue to build a company that is trusted and valued by patients, healthcare professionals and investors.
我也要感謝全球超過 7,000 位同仁不懈努力,致力於帶來更好的健康結果,並持續打造一家受到患者、醫療專業人士與投資人信任與重視的公司。
We entered 2024 with strong momentum and look forward to executing on our strategic objectives, delivering on our commitments as we continue transforming Bausch Health positioning our company for the long term.
我們以強勁動能進入 2024 年,並期待執行我們的策略目標、履行我們的承諾;同時持續推動 Bausch Health 的轉型,為公司長期發展奠定定位。
Thank you for your interest and the support of Bausch Health.
感謝各位對 Bausch Health 的關注與支持。
Operator
Operator
Thank you very much, everyone. This does conclude today's conference. You may disconnect your phone lines at this time and have a wonderful day. Thank you for your participation.
非常感謝各位。今天的會議到此結束。你們現在可以掛斷電話線,祝各位有美好的一天。感謝各位的參與。